SMARCA2 and cancer: ACBI1 recapitulated sensitivities to SMARCA2/4 degradation in cancer cell lines, in a manner not achieved by bromodomain inhibition.113 Emphasising the power of iterative structure-guided design, ACBI1 has been developed via focused and precise structure-guided design modifications, requiring only a limited number of analogues during the medicinal chemistry optimisation campaign, thus avoiding laborious unguided exploration of chemical space.